Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of BioScrip, Inc.
NEW YORK, Sept. 23, 2013 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of BioScrip, Inc. ("BioScrip" or the "Company") (NasdaqGS: BIOS). The investigation focuses on whether the Company and its executives complied with federal securities laws.
On September 23, 2013, Shares of BioScrip fell $0.85 or 7.68% during intraday trading to trade at $10.22 after the Company disclosed in a regulatory filing that on September 11, 2013, it was advised by the government that it plans to engage in discussions with the Company regarding its investigation. As was stated in the Company's 8-K filing, "Pursuant to a civil investigative demand issued by the United States Attorney's Office for the Southern District of New York and a subpoena from the New York State Attorney General's Medicaid Fraud Control Unit, the Company has cooperated by producing documents and information regarding the distribution of the Novartis Pharmaceuticals Corporation product Exjade(R) by the Company's legacy specialty pharmacy division that was divested." BioScrip sold its traditional and specialty pharmacy mail operations and community retail pharmacy stores on May 4, 2012.
If you are aware of any facts relating to this investigation, or purchased shares of BioScrip, you can assist this investigation by contacting either Peretz Bronstein or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email email@example.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484
SOURCE Bronstein, Gewirtz & Grossman, LLC
More by this Source
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Akorn, Inc.
Mar 03, 2014, 16:52 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.